PATENT CLAIM ANALYSIS

Application Number: 15969438
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["424", "184100"]

Abstract:
The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific CD8+ T cells in the presence of tumor-specific, subset specific genetically modified CD4+ T cells, wherein the CD4+ T cells confer and/or augment a CD8+ T cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific CD8+ T cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

Claim (Index 16):
The method according to  claim 11 , wherein at least 60% of the chimeric antigen receptor-modified CD8+ cytotoxic T lymphocytes are derived from a central memory-enriched CD8+ T cell population.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 93.0
- Lexical Diversity: 1.67857
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14006641', '15302415', '13811712', '14873836', '14303385']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8084498223726729
- 35 USC 102 Novelty (BERT): 0.6838432535478269
- Combined Prediction Score: 0.7959891654901883
- Mean Citation Score: 566.48017
- Max Citation Score: 958.6056
- Similarity Product: 668.7845245602608

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test